Repligen (NASDAQ:RGEN) Reaches New 52-Week High – Here’s What Happened

Repligen Corporation (NASDAQ:RGEN) hit a new 52-week high on Wednesday . The company traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares trading hands. The stock had previously closed at $186.75.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. HSBC cut their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. JPMorgan Chase & Co. increased their target price on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Finally, Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $168.57.

Repligen Stock Performance

The firm’s fifty day simple moving average is $163.00 and its 200 day simple moving average is $137.65. The company has a market capitalization of $10.29 billion, a price-to-earnings ratio of 249.58, a PEG ratio of 3.30 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the prior year, the firm earned $0.26 EPS. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts forecast that Repligen Corporation will post 2.06 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, CFO Jason Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

Institutional investors have recently bought and sold shares of the company. Coldstream Capital Management Inc. increased its stake in shares of Repligen by 5.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares in the last quarter. ABS Investment Management LLC bought a new position in Repligen in the 2nd quarter worth $191,016,000. Angeles Wealth Management LLC increased its stake in Repligen by 6.6% in the 2nd quarter. Angeles Wealth Management LLC now owns 2,757 shares of the biotechnology company’s stock worth $376,000 after buying an additional 170 shares in the last quarter. State of Michigan Retirement System increased its stake in Repligen by 1.6% in the 1st quarter. State of Michigan Retirement System now owns 12,753 shares of the biotechnology company’s stock worth $1,503,000 after buying an additional 200 shares in the last quarter. Finally, Summitry LLC raised its holdings in Repligen by 16.3% during the fourth quarter. Summitry LLC now owns 1,741 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 244 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.